Background-Catheter ablation (CA) of ventricular tachycardia (VT) in patients with cardiac sarcoidosis can be challenging because of the complex underlying substrate. We sought to determine the long-term outcome of CA of VT in patients with cardiac sarcoidosis. Methods and Results-We enrolled 31 patients (age, 55±10 years) with diagnosis of cardiac sarcoidosis based on Heart Rhythm Society criteria and VT who underwent CA. In 23 (74%) patients, preprocedure cardiac magnetic resonance imaging and positron emission tomographic (PET) evaluation were performed. Preprocedure magnetic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients, whereas abnormal 18-fluorodeoxyglucose uptake was found in 15 of 23 (65%) cases. In 14 of 15 patients with positive PET at baseline, PET was repeated after 6.1±3.7-month follow-up. After a median follow-up of 2.5 (range, 0-10.5) years, 1 (3%) patient died and 4 (13%) underwent heart transplant. Overall VT-free survival was 55% at 2-year follow-up. Among the 16 (52%) patients with VT recurrences, CA resulted in a significant reduction of VT burden, with 8 (50%) having only isolated (1-3) VT episodes and only 1 patient with recurrent VT storm. The presence of late gadolinium enhancement at magnetic resonance imaging, a positive PET at baseline, and lack of PET improvement over follow-up were associated with increased risk of recurrent VT. Conclusions-In patients with cardiac sarcoidosis and VT, CA is effective in achieving long-term freedom from VT or improvement in VT burden in the majority of patients. The presence of late gadolinium enhancement at magnetic resonance imaging, a positive PET scan at baseline, or lack of improvement at repeat PET over follow-up predict worse arrhythmia-free survival. (Circ Arrhythm Electrophysiol. 2016;9:e004333.
S
arcoidosis is a systemic inflammatory disease characterized by lymphocyte CD4 + -mediated formation of non-necrotizing granulomas. Cardiac involvement is relatively rare and can lead to a wide spectrum of clinical manifestations ranging from potentially reversible AV conduction disorders and atrial arrhythmias, to life-threatening ventricular tachycardia (VT) and severe biventricular heart failure. 1 Myocardial damage is driven by active inflammation with myocyte loss and reparative fibrosis that may progress to biventricular dilation and dysfunction, as well as refractory VT. [2] [3] [4] The management of VT in patients with cardiac sarcoidosis (CS) is challenging, owing to the complexity of the underlying substrate and the progressive nature of the inflammatory process. 5 Previous small series have reported satisfactory short-term VT control with catheter ablation (CA); however, data on long-term outcomes are lacking. We evaluated the long-term outcome of CA of VT in a large series of patients with CS and VT and determined the impact of preprocedure noninvasive imaging modalities on CA outcomes, including cardiac magnetic resonance imaging (MRI) for scar detection and positron emission tomography (PET) for detection of active inflammation-induced glycolytic activity.
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from January 2006 to December 2014 were included in the study. Before the procedure, all patients underwent a comprehensive clinical evaluation, 12-lead ECG, and transthoracic echocardiography comprehensive of left ventricular (LV) and right ventricular (RV) function evaluation. 6 Twenty-three (74%) patients underwent preprocedural cardiac MRI which included late gadolinium enhancement (LGE) imaging for detection of necrosis/fibrosis and PET for detection of abnormal 18-fluorodeoxyglucose (FDG) as a surrogate of myocardial inflammation. All patients gave written informed consent before the procedure. Procedures were performed according to the institutional guidelines of the University of Pennsylvania Health System.
Imaging Studies
Cardiac MRI was performed on a 1.5T scanner (Avanto; Siemens Medical Solutions, Erlangen, Germany) with a cardiac phased-array receiver surface coil and ECG gating. Cine imaging was performed using a steady state free precession sequence in long-axis slices and in a stack of contiguous 6-mm-thick short-axis slices encompassing the whole ventricles. LGE images were acquired using the same slice coverage as long-axis and short-axis cine images 15 minutes after intravenous injection of 0.2 mmol/kg gadobenate dimeglumine contrast agent (Multihance; Bracco Diagnostics, Princeton, NJ) using an inversion-recovery gradient-echo pulse sequence, individually adjusting inversion time to optimize nulling of apparently normal myocardium. 7 In subjects with pacemakers or implantable cardioverter-defibrillators (ICDs), for which strict institutional safety procedures were followed, a wideband LGE sequence was used to minimize artifacts from the battery pack. 8 Biventricular volumes and function were measured using standard volumetric technique from the cine short-axis images. 9 Images were visually assessed for the presence and distribution of LGE areas for each LV myocardial segment using a standard 16-segment cardiac model 10 ; regions of elevated signal intensity had to be confirmed in 2 spatial orientations. Patterns of LGE were visually classified as subendocardial, subepicardial, midmyocardial, and transmural 11 ;
LGE was defined as transmural when occupying ≥75% of LV wall thickness. The endocardial RV surface was divided into 5 regions: RV outflow tract, RV free wall, septum, inferior wall, and peritricuspid-annular region as previously described. 12 PET imaging was performed with a 16-channel PET system (GEMINI TF; Philips Electronics Japan, Tokyo, Japan) after at least 18-hour fasting after a low-carbohydrates and high-fat content meal. The blood glucose before injection was always tested. Images were acquired from the lower neck to the upper abdomen 55 minutes after the injection of 5.034 mCi 18F-FDG. Axial, coronal, and sagittal PET reconstructions were interpreted with and without attenuation correction and regional glucose metabolism in the myocardium was estimate using the same segmentation system described above for MRI. 10 Corresponding computed tomographic images were acquired and reviewed alongside the PET images. The low-dose unenhanced computed tomographic images were used for attenuation correction and anatomic correlation only. FDG uptake was defined as positive if it was greater than that from a physiologically normal liver. 13 To compare longitudinally the results of repeated PET scans, a negative examination or a sensible reduction of the standardized uptake value in involved segments was defined as improvement, whereas an increase in standardized uptake value/number of segments involved was considered as worsening. Whenever there was a comparable number of segments involved and mean standardized uptake value between the baseline and follow-up examinations, the PET was considered unchanged.
Electroanatomical Mapping and CA
Patients presented to the cardiac electrophysiology laboratory in the fasting state. Conscious sedation was used whenever possible. Catheters were positioned in the heart using fluoroscopic guidance. A 6F quadripolar catheter with 5-mm interelectrode distance (Bard Inc., Delran, NJ) was placed at the RV apex. A deflectable 8F mapping/ablation catheter that had a 3.5-mm irrigated tip and a 2-mm ring electrode separated by 1 mm (Thermocool, Biosense Webster, Diamond Bar, CA) was advanced to the RV (transvenous approach), LV (retrograde aortic or transseptal approach), or epicardial space according to the presumed site of origin of the VT or the underlying substrate. A high-density (color and surface fill threshold <15 mm) 3-dimensional electroanatomic map (EAM; CARTO; Biosense Webster, Inc., Diamond Bar, CA) was created during sinus or paced rhythm to identify low-voltage areas (LVAs) and abnormal electrograms consistent with scar. Reference values for identifying abnormal endocardial bipolar and unipolar and epicardial bipolar electrogram signal amplitudes in the RV and LV were defined according to previously established criteria. [14] [15] [16] [17] An endocardial bipolar signal amplitude of >1.5 mV, an epicardial bipolar signal amplitude of >1.0 mV either in the RV and LV, and an endocardial unipolar signal amplitude of >8.3 mV in the LV and >5.5 mV in the RV were categorized as normal and represented in the EAM by purple color. Abnormal voltage areas were represented by nonpurple range of colors, with the most abnormal signal amplitude (arbitrary defined as <0.5 mV) represented by red color. The decision for an epicardial approach was made when (1) the 12-lead ECG of the VT suggested an epicardial origin; (2) there was evidence of epicardial substrate on imaging studies (eg, magnetic resonance and intracardiac echocardiography); (3) unipolar electrogram abnormality (<8.3 mV) in the presence of no or minimal bipolar (<1.5 mV) electrogram abnormality; and (4) failure of endocardial ablation procedure. Access to the pericardial space and epicardium was obtained using the percutaneous subxiphoid approach described by Sosa et al. 18 A 64-element phased-array intracardiac echocardiography catheter (AcuNav, Acuson, Mountain View, CA) was used to assist catheter manipulation, radiofrequency energy delivery, and tissue-catheter contact and monitor for complications. Programmed ventricular stimulation was performed and induced VT(s) were compared with those occurring spontaneously. Induced VT(s) were identified as clinical if they matched the cycle length and morphology of stored implantable cardioverter defibrillator electrograms (near-field and far-field) and the 12-lead ECG when available. Prioritization was made to eliminate the clinical VT(s) and all mappable nonclinical VT(s). All induced VT(s) with a cycle length within >250 ms were also considered
WHAT IS KNOWN
• Myocardial damage in cardiac sarcoidosis is driven by active inflammation with myocyte loss and reparative fibrosis, providing the substrate for ventricular arrhythmias.
• Ablation of ventricular tachycardia is challenging, owing to the complexity of the underlying substrate and the progressive nature of the inflammatory process. Data on long-term outcomes after catheter ablation as well as the relation of pre-procedure imaging data to ablation outcomes are limited.
WHAT THE STUDY ADDS
• Catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis can achieve long-term arrhythmia control in most patients.
• Noninvasive imaging studies (MRI and PET) were not useful in identifying the key regions of substrate to be targeted with catheter ablation.
• The extent of scar at MRI together with either positive PET imaging at baseline or lack of improvement at repeat PET imaging over follow-up, predict worse arrhythmia-free survival.
potentially relevant and routinely targeted for ablation. For hemodynamically tolerated VT(s), entrainment mapping was performed within the LVA at sites showing diastolic activity to identify critical sites of the VT re-entrant circuit. A critical site that was appropriate target for ablation was defined as a site showing entrainment with concealed QRS fusion and return cycle within 30 ms of the VT cycle length with matching stimulus-QRS and electrogram-QRS intervals or where VT terminated during pacing without global capture. 19, 20 Radiofrequency energy was delivered at these sites using powers up to 50 W with a goal 10-to 15-Ohm impedance drop. For hemodynamically unstable VTs, substrate modification was performed with linear or cluster lesions targeting sites identified by pace mapping and late potentials, as previously described. 15 After ablation, programmed stimulation was repeated with up to 3 ventricular extrastimuli delivered from 2 different sites at 2 pacing cycle lengths until refractoriness. Procedural success was defined as lack of inducibility of the clinical VT(s) and of all the mappable and unmappable nonclinical induced VT(s) with cycle length of >250 ms. Although the acute procedural end points changed over time with the adoption of more stringent criteria to define acute procedural success, the ablation strategy remained consistent throughout the years and included endocardial substrate modification with adjuvant epicardial mapping and ablation when the procedural end point was not met, namely, in case of recurrent VT or persistent inducibility following endocardial-only procedures.
Analysis of the Electroanatomic Substrate
LVAs were manually contoured, and their extent was expressed in cm 2 and percentages of the whole surface using the CARTO area measurement tool. To minimize the effect of epicardial fat on LVA measurements, the anterior interventricular sulcus and the AV groove (defined as the first centimeter from mitral and tricuspid annuli) were not considered for segmentation when contouring epicardial LVAs. 21 To further limit the influence of epicardial fat and small-vessel coronary vasculature (ie, vessels that cannot be directly appreciated by coronary angiogram) on the low-voltage region, the contiguous lowvoltage electrograms had to demonstrate not only a low amplitude but also signals with discrete late potentials (recorded after the QRS of the surface ECG) and demonstrate broad multicomponent or split signals within the boundary of the defined contiguous low-voltage abnormality.
To compare the location of LVA with location of LGE on MRI and abnormal FDG uptake on PET images, the presence and distribution of LVA were assessed for each LV and RV myocardial segment using the same LV 16-segment and RV 5-segment cardiac model described above. 10 A separate 11-segment model (4 basal and midsegments: anterior, anterolateral, inferolateral, and inferior and 3 apical segments: anterior, lateral, and inferior) was used for the LV epicardium as previously described.
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Outcomes
Acute procedural outcomes included (1) noninducibility of the clinical VT and (2) noninducibility of any VT with cycle length of >250 ms. Long-term outcomes included (1) survival free of any VT (defined as any sustained VT on ICD interrogation or 12-lead ECG) after single or multiple procedures, (2) reduction of VT burden defined as any reduction in the number of VT episodes, and (3) survival free of death or cardiac transplantation. Survival free of VT recurrence, death, or cardiac transplant in patients with evidence of active inflammation versus those with inactive disease based on PET results was also reported.
Clinical Follow-Up
Patients were routinely evaluated at 4 to 8 weeks after ablation and then at 3-to 6-month intervals. For patients not followed up at our institution, the referring cardiologists were contacted and ICD interrogations reviewed to determine VT recurrence. Telephone interviews were performed at 6-and 12-month intervals with patients or family members to confirm the absence of arrhythmias symptoms. The Moderate to severe right ventricular dysfunction, n (%)
(19)
Moderate to severe diastolic dysfunction, n (%) 11 ( 
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Social Security Death Index database was also searched for mortality information.
Statistical Analysis
Continuous variables were expressed as mean±SD if normally distributed or median (interquartile range, 25th-75th percentile) if not normally distributed. All continuous variables were tested for normal distribution using the 1-sample Kolmogorov-Smirnov test. Categorical data were expressed as counts and percentages. Continuous variables were compared using independent-sample parametric (unpaired Student t test) or nonparametric (Mann-Whitney U test) tests. Different variables among the same patients were compared using paired-sample parametric (paired Student t) or nonparametric (paired Wilcoxon signed-rank) tests. Categorical variables were compared using χ 2 test or Fisher exact test when appropriate. The agreement between different imaging modalities and EAM was assessed using Cohen κ coefficient. Survival curves were generated by the Kaplan-Meier method and compared by the log-rank test. Single variable Cox proportional hazards analysis was used to test the association between the outcome event and baseline covariates. Receiver operating characteristic curve analysis was performed to determine the optimal cutoff value for LGE extent on MRI. Two-tailed tests were considered statistically significant at the 0.05 level. All the analysis were performed using IBM SPSS version 23.0 software (SPSS Inc, Chicago, IL).
Results
Characteristics of the Patient Sample
Clinical features of the study sample are summarized in Table 1 . The mean age of the patients at the time of referral for CA was 55±10 years. In all the patients, the diagnosis of CS was based on Heart Rhythm Society criteria.
1 Specifically in 5 of 31 (16%) patients, diagnosis of CS was based on endomyocardial biopsy and in 4 (13%) on histological examination of explanted heart during follow-up at the time of transplant. The remaining 22 (71%) had an histological diagnosis of extra-CS and MRI and PET consistent with cardiac involvement by the disease. 1 In 23 (74%) patients, the first clinical manifestation of cardiac involvement was a ventricular arrhythmia, sustained VT in 13 (42%) of the cases, and frequent premature ventricular contraction/nonsustained ventricular tachycardia in 10 (32%). Complete AV block was the first manifestation in the remaining 8 (26%) patients. The median time from the outset of cardiac disease and the development of sustained VT was 2 (0-7) years. The indication for VT ablation was multiple recurrent VT episodes refractory to treatment with 2 (1-3) antiarrhythmic drugs in 28 (90%) patients and VT storm in the remaining 3 (10%) patients. The sustained VT burden during the 6 months preceding the procedure was 10 (3-22) episodes per patient. At the time of ablation, 22 (71%) patients were receiving immunosuppressive therapy for active disease (biopsy or PET proven) with prednisone with addition of methotrexate in 6 (19%) because of the lack of response to prednisone alone. PET trend among patients with repeated scan, n (%) 
Imaging Findings
Imaging findings are summarized in Table 2 . Twenty-three of 31 (74%) patients underwent MRI and PET evaluation before the procedure. Preprocedure MRI was positive for LGE in 21 (91%) patients, whereas abnormal FDG uptake was found in 14 (61%). The LV distribution of LGE on MRI and of abnormal FDG uptake on PET are illustrated in Figure 1A and 1B. The LV was more involved by the disease than the RV both in terms of presence of necrosis/fibrosis (68% of the patients with LV involvement versus 36% with RV involvement; P=0.013) and active inflammation on PET (65% versus 4%; P<0.001).
In the majority of patients with evidence of necrosis/fibrosis on MRI the distribution of LGE was midmyocardial and subepicardial (32% and 39% of patients, respectively) with 10 (32%) patients showing evidence of transmural extension. A median of 5 (2-6) LV segments was involved by LGE with a greater involvement of the basal septum and perivalvular regions (95% of the patients with basal involvement versus only 13% with apical involvement; P<0.001). In the 2 patients with no evidence of LGE on MRI, the clinical presentation was sustained monomorphic VT. Both patients had evidence of abnormal electroanatomic substrate involving the basal LV septum and anterior wall (endoepicardial in one patient) and RV free wall (endoepicardial in the other patient).
The extent of inflammation in the LV was similar to the extent of necrosis/fibrosis with a median number of 4 involved segments (0-8; P=0.094), with a distribution similar to LGE.
Among the 14 patients with positive PET at baseline, PET was repeated within 6-month follow-up. Improvement in FDG uptake was noted in 7 (50%) cases, increased uptake or unchanged in the remaining patients (further details are available in the Data Supplement). 
Electroanatomical Mapping
The main findings from EAM are summarized in Table 3 . Endocardial mapping was performed in all patients and epicardial mapping in 11 (35%). The LV endocardium was mapped in 21 (68%) patients and the RV endocardium in 18 (58%). All the maps were high density without difference between LV and RV (1.2±0.7 versus 1.3±0.6 points/cm 2 in the LV and RV, respectively; P=0.399). The distribution of bipolar and unipolar LVA among LV endocardium and epicardium is illustrated in Figure 1C through 1E.
LV endocardial bipolar LVAs were present in 16 of 21 (76%) patients extending through 8% (2%-18%) of the LV endocardial surface with a predominant involvement of the basal septum in 12 of 21 (57%) patients and the anterior basal wall in 7 of 21 (33%). Unipolar LVAs were present in all the patients involving 27% (15%-40%) of the LV endocardial surface and were most commonly located in the basal segments (20/21: 95% of patients with basal septal involvement, 13/21: 62% with anterior basal, 13/21: 62% with anterolateral basal, 13/21: 62% with inferolateral basal, and 14/21: 67% with inferior basal segments).
RV bipolar LVAs were present in 15 of 18 (83%) patients, involving 12% (1%-26%) of the RV endocardial surface. The most common location were the RV outflow tract in 10 of 18 (56%) patients and the basal septum in 10 of 18 (56%) followed by the free wall/peritricuspid-annular region in 6 of 18 (33%) and the inferior wall in 4 of 18 (20%). Unipolar LVAs were present in 17 of 18 (94%) patients and extended for 24% (12%-75%) of the RV endocardial surface with a predominantly perivalvular distribution similar to the bipolar LVA.
Epicardial bipolar LVAs were present in all the 11 patients who underwent epicardial mapping and the median extent was 7% (13%-74%) of the epicardial surface. The RV and LV anterior basal free wall and the LV anterolateral basal wall were the most involved segments in 7 of 11 (64%) and 3 of 11 (27%) patients.
The results of the segmental analysis evaluating the agreement between LVAs on EAM and LGE on MRI and abnormal FDG uptake on PET are shown in Table 4 . The best agreement was found between MRI and endocardial unipolar (K=0.4; P<0.001) and epicardial bipolar (K=0.5; P<0.001) voltage abnormalities. Lower agreements were found with PET. Endocardial and epicardial fragmented, late, and split potentials were found in all patients. Endocardial fragmented, late, and split potentials were present in 22% of LV segments most commonly within basal segments, midseptum, and midanterior wall. Epicardial fragmented, late, and split potentials were present in all patients who underwent epicardial mapping with a prevalent distribution in the midbasal segments. Abnormal electrograms were found outside bipolar LVA in 38% of cases within the LV endocardium, 20% cases within the RV endocardium, and 21% cases within epicardium.
CA and Acute Procedural Outcomes
The main characteristics of the ablation procedures are summarized in Table 5 . A total of 44 procedures were performed among 31 patients to achieve good arrhythmia control. Nine (29%) patients underwent a second procedure and in 2 (6%) cases a third procedure was performed. Sixteen of 44 procedures were performed under general anesthesia, and in 2 cases mechanical hemodynamic support was used because of hemodynamic instability. The baseline clinical arrhythmia was monomorphic VT in 28 of 31 (90%) patients and polymorphic VT in the remaining 3 of 31 (10%), multiple VT morphologies were observed in 15 of 31 (48%) patients. A median number of 3 (1-5) different VTs were induced in 44 procedures with a mean cycle length of 369±77 ms. The clinical VT defined by electrogram match with similar cycle length was always induced. At least 1 hemodynamically nontolerated VT was also inducible in 12 of 31 (39%) patients. Detailed activation/ entrainment mapping was possible in only 16 of 44 (36%) procedures, whereas the remaining 28 (64%) procedures were completed with a prevalent substrate-based approach in sinus rhythm with only limited entrainment/activation mapping because of either poor hemodynamic stability or noninducibility of the clinical VT at baseline. All the patients underwent endocardial mapping and ablation, whereas epicardial mapping was performed in 11 of 31 (35%) and epicardial ablation in 8 of 31 (26%) patients. At the end of the last procedure, the clinical VT was still inducible in 3 of 31 (10%) patients whereas in 6 of 31 (19%) cases at least 1 nonclinical VT remained inducible. A major complication occurred in 2 procedures (4.5%): 1 perforation of the coronary sinus requiring surgical repair, and 1 developed a total occlusion of a small coronary artery branch (obtuse marginal) during epicardial ablation.
Long-Term Outcomes
The natural history of the studied sample is schematically represented as a timeline in Figure 4 . After a median follow-up of 2.5 (1.3-5.2; range, 0-10.5) years, 4 patients underwent heart transplantation and a single patient died. Overall death/ transplant-free survival was 90% and 83%, respectively, at 1-and 2-year follow-up ( Figure 5A ). After the first ablation procedure, 2 patients underwent a second procedure within 3 days because of persistent inducibility of the clinical VT at the end of the procedure, 18 patients experienced VT recurrence and 7 of them underwent a second ablation procedure within 151 (55-315) days, only 2 patients underwent a third procedure after 249 (140-359) days from the second one. The cumulative 1-and 2-year free survival from any VT after the last procedure was 71% and 55%, respectively ( Figure 5B ). In the remaining 16 (60%) patients, CA resulted in a substantial reduction of VT burden with 4 of 16 (25%) having a single episode of sustained VT over a median of 1.4 (0.6-2.7) years of follow-up, 8 of 16 (50%) patients having ≤3 VT episodes over a median of 1.7 (0.6-3.2) years of follow-up, and only a single patient having recurrent VT storm ( Figure 5C ). The sustained VT burden during the 6 months after the last procedure was 1 (0-5) episodes per patient.
Four of 31 patients presented with frequent premature ventricular contraction/nonsustained ventricular tachycardia as the main indication for VT ablation although all of them experienced at least 1 episode of sustained VT before the procedure leading to appropriate ICD interventions. One of 4 patients had VT recurrence within 48 hours after the ablation procedure and underwent heart transplant within 1 month. One patient remained free from any ventricular arrhythmia for 3 years and then experienced 3 sustained VT episodes and the last 2 patients were free from any ventricular arrhythmia at last follow-up.
A better outcome in terms of VT recurrence was observed in patients with negative baseline PET (6-year follow-up free survival from any VT: 65% versus 11%, respectively, log-rank P=0.028) or with PET improvement after immunosuppressive therapy (6-year follow-up free survival from any VT: 43% versus 0%, respectively, log-rank=0.026).
Extent of LGE on MRI was also found to predict VT-free survival. Among patients with positive MRI, receiver operating characteristic curve analysis allowed to identify a cutoff of 6 segments (area under the curve, 0.63; 95% confidence interval [CI], 0.39-0.88) involved by LGE that best identified patients at increased risk of VT recurrence. After stratifying patients according to this cutoff, a significant lower recurrence rate was observed among those with a more limited LGE extent (6-year free survival from any VT 51% versus 0%, logrank P=0.035). 
Discussion
The present study reports the results of CA of drug-refractory VT in a large series of patients with CS, with the longest follow-up to date. The major findings are as follows: (1) CA of VT in patients with CS is a safe and effective approach to achieve long-term arrhythmia control in most patients; (2) noninvasive imaging studies such as MRI and PET may help to identify patients at higher risk of recurrent VT after ablation; (3) patients with a baseline positive PET or with lack of improvement of PET over follow-up have the highest risk of recurrent VT after ablation.
The management of recurrent VT in the setting of CS is challenging, and evidence supporting different treatment strategies mainly stems from small retrospective studies with discordant outcomes and arrhythmia-free survival ranging from 25% to 57% (Table 7) . 2, 4, 12, 23, 24 Our findings confirm and extend the results of the previous studies and show that endocardial with adjuvant epicardial mapping and CA when indicated (ie, recurrent VT or persistent inducibility after endo-only ablation) provides good long-term outcomes, with 40% of patients having no VT at 6-year follow-up and infrequent or isolated recurrent episodes in most of the remaining patients ( Figure 5) . However, the efficacy of CA in this patient sample certainly seems lower than other patient cohorts with scar-related VT. 15, 25, 26 In CS, unlike other forms of scar-related VTs, active inflammation plays a role in promoting VT either by triggered activity or abnormal automaticity or by creating functional slow-conduction pathways within inflamed tissue. 3, 27 On the contrary, a benefit of anti-inflammatory medical therapy to address inflammation in patients presenting with VT has never been convincingly proven. 3, 4, [28] [29] [30] In 74% of our patients, an accurate disease-staging comprehensive of scar assessment with MRI and active inflammation assessment with PET was performed before CA. Immunosuppressive treatment with corticosteroids was started before the procedure in those with evidence of active disease and a 3-to 6-month PET follow-up for evaluating steroid response was scheduled. We found that evidence of active inflammation at baseline PET strongly influences long-term procedural outcomes with a 4-fold risk of VT recurrence for those patients with positive baseline PET and an adjunctive 2-fold risk for those with lacking of PET improvement after immunosuppressive therapy. These data would support a benefit of preprocedure imaging to evaluate the presence of active inflammation to identify patients at higher risk of recurrent VT after ablation in whom a more aggressive medical therapy with immunosuppressive drugs may be helpful to improve outcomes. Finally, despite arrhythmic control, 17% of cases underwent heart transplant or died during follow-up. However, in these patients, recurrent VT was not the cause of death or heart transplant.
Limitations
This was an observational study summarizing a single-center experience. The study sample was relatively small although one of the largest series for this rare condition. Given the small number of events, we could not perform multivariable analysis, which might not have sufficient power to show independent predictors of outcomes. Detailed data on device programming in individual patients were not available; however, a VT zone able to detect the slowest clinical and induced VT was always included, thus minimizing the risk of underestimation of recurrent VT episodes after CA.
A segmental analysis was performed instead of a point by point for 2 reasons: (1) several patients had devices (ICDs or pacemakers), and the LGE sequences had significant artifacts, which made a point-by-point analysis difficult, but still allowed for a good segmental analysis; (2) this study also includes PET data, and our tools have yet to be adapted to the analysis of PET data and have never been used for this LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; NYHA, New York Heart Association; PET, positron emission tomography; RV, right ventricle; and VT, ventricular tachycardia. 31 In this regard, it is possible that the variable fat extension in the epicardium may have affected the analysis of epicardial LVAs. In addition, T2-weighted imaging, which may allow the identification of myocardial edema possibly representing an arrhythmogenic substrate among those patients without detectable LGE, was not routinely performed. However, only 2 patients had no evidence of LGE on cardiac MRI and they underwent PET, and all the patients underwent PET scan to evaluate active inflammation even if T2-imaging was not performed.
The lack of complete mapping data for every patient (LV, RV, endocardial, and epicardial) was a limit for the comparison with MRI and PET data. Correlation analyses were made only between chambers mapped and the corresponding chamber(s) on MRI/PET.
Conclusions
CA of VT in patients with CS is able to provide long-term arrhythmia-free survival in 40% of patients with a significant reduction of the arrhythmic burden in up to 90% of cases. The benefit seemed consistent also in patients on active immunosuppressive therapy. Preprocedural imaging with MRI and PET scan is helpful to identify patients at higher risk of arrhythmia recurrence after the procedure. However, the utility of LGE or PET to predict/guide ablation strategy seemed limited.
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